Omalizumab: Monoclonal antibody against IgE;Omalizumab: Monoklonaler antikörper gegen IgE

Medizinische Monatsschrift fur Pharmazeuten

Volumn 27, Issue 12, 2004, Pages 404-407

  Hennemann, Alexandra ^a  

^a Deutscher Apotheker Verlag Dr Roland Schmiedel GmbH & Co   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; FC RECEPTOR; GLUCOCORTICOID; HISTAMINE; IMMUNOGLOBULIN E; LEUKOTRIENE; MONOCLONAL ANTIBODY; OMALIZUMAB; PLACEBO; POLLEN ANTIGEN; PROSTAGLANDIN;

ALLERGIC ASTHMA; ALLERGIC RHINITIS; ASTHMA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG CONTRAINDICATION; DRUG HYPERSENSITIVITY; DRUG INDICATION; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOTHERAPY; LUNG FUNCTION; MAJOR CLINICAL STUDY; PATHOGENESIS; PHASE 3 CLINICAL TRIAL; POLLEN ALLERGY; SHORT SURVEY;

ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; DRUG INTERACTIONS; HUMANS; IMMUNOGLOBULIN E;

EID: 10844266577     PISSN: 03429601     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (7)

1. Kroegel C. Antikörper bei allergischen Erkrankungen. Arzneimitteltherapie 2002;20:226-37.
2. Xolair®. Label der Food and Drug Administration (FDA). http:// www.fda.gov/cder/foi/label/2003/omalgen062003LB.pdf.
3. FDA approves first biologic for allergy-related asthma. FDA Talk Paper vom 20. Juni 2003. http://www.fda.gov/bbs/topics/ANSWERS/2003/ ANS01236.html.
4. Omalizumab. Drugdex Drug Evaluations. Ausgabe 120, 2. Quartal 2004.
5. Casale TB. Omalizumab: An effective anti-IgE treatment for allergic asthma and rhinitis. Drugs of Today 2004;40:367-76.
6. Ladetzki-Baehs K, Dirsch VM, Vollmar AM. Omalizumab: Vom IgE zum Anti-IgE. Pharm Unserer Zeit 2004;33:116-22.
7. Thews G, Mutschler E, Vaupel P, Anatomie, Physiologie, Pathophysiologie des Menschen. Stuttgart: Wissenschaftliche Verlagsgesellschaft 1999:292.